{"id":"https://openalex.org/W27552111","doi":null,"title":"[Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis(review)].","display_name":"[Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis(review)].","publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W27552111","mag":"27552111","pmid":"https://pubmed.ncbi.nlm.nih.gov/23675607"},"language":"ru","primary_location":{"id":"pmid:23675607","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23675607","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","raw_type":"English Abstract"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112212335","display_name":"\u0410. \u041d. \u0411\u043e\u0439\u043a\u043e","orcid":"https://orcid.org/0000-0003-2697-7605","observed_orcids":["https://orcid.org/0000-0003-2697-7605","https://orcid.org/0000-0003-3306-9541"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A N Bo\u012dko","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5036549747","display_name":"Evgeny I. Gusev","orcid":"https://orcid.org/0000-0003-0742-6875","observed_orcids":["https://orcid.org/0000-0003-0742-6875"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E I Gusev","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1978,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.54324998,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"113","issue":"2 Pt 2","first_page":"93","last_page":"9"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/laquinimod","display_name":"laquinimod","score":1.0},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.996999979019165},{"id":"https://openalex.org/keywords/oral-therapy","display_name":"oral therapy","score":0.9449999928474426},{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.9539999961853027},{"id":"https://openalex.org/keywords/immunomodulation","display_name":"immunomodulation","score":0.8930000066757202},{"id":"https://openalex.org/keywords/anti-inflammatory-activity","display_name":"anti-inflammatory activity","score":0.8109999895095825},{"id":"https://openalex.org/keywords/relapse-rate","display_name":"relapse rate","score":0.9580000042915344},{"id":"https://openalex.org/keywords/disability-progression","display_name":"disability progression","score":0.996999979019165},{"id":"https://openalex.org/keywords/brain-atrophy","display_name":"brain atrophy","score":0.984000027179718},{"id":"https://openalex.org/keywords/magnetic-resonance-imaging","display_name":"magnetic resonance imaging","score":0.3970000147819519},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.7820000052452087},{"id":"https://openalex.org/keywords/phase-ii-and-iii-clinical-trials","display_name":"phase II and III clinical trials","score":0.7910000085830688}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9486401081085205},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8151388168334961},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.777227520942688},{"id":"https://openalex.org/C25498285","wikidata":"https://www.wikidata.org/wiki/Q1981368","display_name":"Neuroprotection","level":2,"score":0.7182008028030396},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6797218322753906},{"id":"https://openalex.org/C2781172350","wikidata":"https://www.wikidata.org/wiki/Q194520","display_name":"Atrophy","level":2,"score":0.5479762554168701},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4856525659561157},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38527846336364746},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3690961003303528},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33281952142715454},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.13367518782615662}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:23675607","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23675607","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","raw_type":"English Abstract"},{"id":"mag:27552111","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23675607","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":45,"referenced_works":["https://openalex.org/W4250145052","https://openalex.org/W1983692527","https://openalex.org/W2123021165","https://openalex.org/W2104188690","https://openalex.org/W2022481930","https://openalex.org/W2037320008","https://openalex.org/W2132651155","https://openalex.org/W2141111992","https://openalex.org/W1484629663","https://openalex.org/W2102697241","https://openalex.org/W2128402413","https://openalex.org/W1970875728","https://openalex.org/W2043316586","https://openalex.org/W2151492920","https://openalex.org/W2008878369","https://openalex.org/W2105167551","https://openalex.org/W1600867898","https://openalex.org/W2040890202","https://openalex.org/W2050492409","https://openalex.org/W1510197257","https://openalex.org/W2076291065","https://openalex.org/W2160169597","https://openalex.org/W2122522635","https://openalex.org/W2048362681","https://openalex.org/W2096243634","https://openalex.org/W2126336004","https://openalex.org/W2489481562","https://openalex.org/W2128964123","https://openalex.org/W2054268831","https://openalex.org/W2074421911","https://openalex.org/W2064531937","https://openalex.org/W2051655508","https://openalex.org/W2142659101","https://openalex.org/W2105053272","https://openalex.org/W2118818657","https://openalex.org/W2160872052","https://openalex.org/W2313484897","https://openalex.org/W2015285729","https://openalex.org/W1688265474","https://openalex.org/W1977749342","https://openalex.org/W2042927558","https://openalex.org/W2128600935","https://openalex.org/W2107635082","https://openalex.org/W1822128789","https://openalex.org/W2475012987"],"related_works":["https://openalex.org/W1984043350","https://openalex.org/W1974105449","https://openalex.org/W2145054670","https://openalex.org/W2093541546","https://openalex.org/W2301523002","https://openalex.org/W2073506337","https://openalex.org/W1975841079","https://openalex.org/W2101539564","https://openalex.org/W2087704334","https://openalex.org/W2051591416"],"abstract_inverted_index":{"New":[0],"oral":[1,26],"therapies":[2],"of":[3,20,52,63,85,127],"MS":[4,29,58,100],"cause":[5],"great":[6],"attention.":[7],"This":[8],"review":[9],"includes":[10],"data":[11,115],"on":[12,65],"the":[13,77,86,110,124],"II":[14,112],"and":[15,34,42,48,68],"III":[16,54],"phase":[17,53,111],"clinical":[18,72,97],"studies":[19,55],"laquinimod":[21],"(LAQ)":[22],"-":[23],"a":[24,44,82],"new":[25],"therapy":[27],"for":[28],"with":[30],"immunoregulatory,":[31],"anti":[32],"inflammatory":[33],"neuroprotective":[35],"action.":[36],"LAQ":[37,64,96],"has":[38,43],"no":[39],"immunosuppressive":[40],"effects":[41],"very":[45],"good":[46],"safety":[47],"tolerability":[49],"profile.":[50],"Data":[51],"including":[56],"2437":[57],"patients":[59,101],"confirmed":[60],"positive":[61],"effect":[62],"relapse":[66],"rate":[67],"disability":[69],"progression.":[70],"These":[71],"results":[73],"were":[74],"supported":[75],"by":[76],"MRI":[78],"data,":[79],"showing":[80],"also":[81],"significant":[83],"slowing":[84],"brain":[87],"atrophy.":[88],"Russian":[89],"neurological":[90],"clinics":[91],"actively":[92],"participated":[93],"in":[94,109,116,123],"all":[95,120],"trials:":[98],"241":[99],"from":[102,105],"11":[103],"centers":[104],"Russia":[106],"took":[107],"part":[108],"trials.":[113],"The":[114],"this":[117],"subgroup":[118],"confirm":[119],"changes,":[121],"registered":[122],"whole":[125],"group":[126],"patients.":[128]},"counts_by_year":[{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2016-06-24T00:00:00"}